Taysha Gene Therapies Inc (NASDAQ:TSHA) has a beta value of 0.34 and has seen 1.06 million shares traded in the recent trading session. The company, currently valued at $467.55M, closed the recent trade at $2.50 per share which meant it gained $0.11 on the day or 4.60% during that session. The TSHA stock price is -55.6% off its 52-week high price of $3.89 and 80.0% above the 52-week low of $0.50. The 3-month trading volume is 2.78 million shares.
Taysha Gene Therapies Inc (NASDAQ:TSHA) trade information
Sporting 4.60% in the green today, the stock has traded in the green over the last five days, when the TSHA stock price touched $2.50 or saw a rise of 4.21%. Year-to-date, Taysha Gene Therapies Inc shares have moved 41.24%, while the 5-day performance has seen it change 1.63%. Over the past 30 days, the shares of Taysha Gene Therapies Inc (NASDAQ:TSHA) have changed -12.89%.
Taysha Gene Therapies Inc (TSHA) estimates and forecasts
Figures show that Taysha Gene Therapies Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 2.88% over the past 6 months, with this year growth rate of 59.38%, compared to 21.80% for the industry. Other than that, the company has, however, increased its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are 60.70% and 71.10% for the next quarter. Revenue growth from the last financial year stood is estimated to be -33.70%.
9 analysts offering their estimates for the company have set an average revenue estimate of $2.56 million for the current quarter. 9 have an estimated revenue figure of $2.57 million for the next quarter concluding in Jun 2024. Year-ago sales stood $4.71 million and $2.4 million respectively for this quarter and the next, and analysts expect sales will shrink by -45.60% for the current quarter and 7.30% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -137.69% over the past 5 years.
TSHA Dividends
Taysha Gene Therapies Inc is expected to release its next earnings report in May this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
